Table 3. Survival analysis.

Model	HR	(95% CI)	P	ER status interaction P a	ER status heterogeneity P b
All-cause mortality
Co-dominant
All tumours (unadjusted)	1.02	(0.88–1.19)	0.78
All tumours (adjusted)c	1.01	(0.81–1.25)	0.95
ER+ tumours onlyd	1.17	(0.82–1.66)	0.39
ER− tumours onlyd	0.94	(0.71–1.24)	0.66	0.74	0.34
AG/GG vs AA
All tumours (unadjusted)	0.92	(0.74–1.15)	0.74
All tumours (adjusted)c	0.83	(0.61–1.13)	0.24
ER+ tumours onlyd	0.80	(0.50–1.28)	0.36
ER− tumours onlyd	0.87	(0.57–1.32)	0.52	0.54	0.80
Breast-cancer-specific mortality
Co-dominant
All tumours (unadjusted)	1.03	(0.87–1.22)	0.72
All tumours (adjusted)c	1.02	(0.81–1.28)	0.89
ER+ tumours onlyd	1.07	(0.72–1.59)	0.75
ER− tumours onlyd	1.02	(0.77–1.37)	0.87	0.72	0.87
AG/GG vs AA
All tumours, unadjusted	0.92	(0.73–1.16)	0.47
All tumours (adjusted)c	0.84	(0.60–1.18)	0.33
ER+ tumours onlyd	0.75	(0.44–1.25)	0.27
ER− tumours onlyd	0.96	(0.61–1.50)	0.84	0.31	0.48

Abbreviation: CI=confidence interval; ER=oestrogen receptor; HR=hazards ratio.

HRs, 95% CIs and P-values under co-dominant and dominant C1qA rs172378 genotype models for all-cause and breast-cancer-specific mortality.

^aFormal test for interaction (effect beyond additive) between C1qA genotype and ER status.

^bOne degree of freedom χ²-test for heterogeneity between ER+/− tumor HRs.

^cModels adjusted for age at diagnosis (<40, 40–49, 50–59, 60+), TNM stage, histopathological grade and stratified by ER status.

^dModels adjusted for age at diagnosis (<40, 40–49, 50–59, 60+), TNM stage, histopathological grade.